Patients who receive an add-on medication soon after a heart attack have a significantly better prognosis than those who receive it later, or not all, new research suggests. Patients who receive an ...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results